DATAR

'La France moche': French artists rally to celebrate the country's much-snubbed commercial zones

Retrieved on: 
Wednesday, October 4, 2023

France counts no less than 1,500 of them, equivalent to an area of 500 km2, or 5 times the size of Paris.

Key Points: 
  • France counts no less than 1,500 of them, equivalent to an area of 500 km2, or 5 times the size of Paris.
  • 72% of spending by French households takes place within them, according to the country’s economy ministry.
  • If that is to happen, we French people will have to learn to look at what are now often commercial ghettos under a new light.

“Ugly France”: a subjective perspective

    • First used in the pages of the cultural magazine Télérama in 2010, the expression encapsulates the forms that urban spread takes: road infrastructure, commercial zones and housing developments.
    • Never mind that a third of the population resides in these districts, in a mosaic of different socio-economic classes and diverse and changing living arrangements.
    • The sheer number of ads in all forms in the central areas of the capital constitute the perfect example.
    • Artists, and photographers in particular, have produced much work that can enable us to appreciate this aspect of commercial zones.

When artistic production meets town planning

    • The fascination of photographers for suburban spaces first manifested itself during the Photographic Project of DATAR (Interministerial Delegation for Urban Planning and Regional Attractivity).
    • DATAR was created in 1963 with the aim of documenting the national politics of urban planning.
    • In 1984, Bernard Latarjet and François Hers founded the project in order to “represent the French landscape of the 1980s” and to “recreate a culture of landscapes”.

New stories

    • Initiated by the Forum Vies Mobiles (a mobility research unit), “The lives we lead” seeks to capture the diversity of contemporary ways of life in France.
    • The photography series capture stories, following individuals from all backgrounds, in different regions.
    • Far from simply documenting, the project focuses on narration, featuring the inhabitants of suburban zones with vivid evocative power.

The aesthetic of contrast

    • They are animated by nostalgia, off-beat humour, or are inspired by cinematic influences.
    • Commercial zones become stories, and their visual qualities, full of contrasts, are sublimated by the art.
    • “Hexagone : le paysage fabriqué” de Jurgen Nefzger montre des paysages périurbains dotés points de repères et de monumentalité.
    • Her series ‘Hyperlife’ reveal the social relationships that play out on the carpark of the Intermarché supermarket of Saint-Erme (Hauts-de-France).

Harvard Business School Celebrates 113th Commencement

Retrieved on: 
Friday, May 26, 2023

BOSTON, May 26, 2023 /PRNewswire/ -- Harvard Business School (HBS) held its 113th Commencement exercises yesterday with a diploma ceremony on its campus in Boston.

Key Points: 
  • BOSTON, May 26, 2023 /PRNewswire/ -- Harvard Business School (HBS) held its 113th Commencement exercises yesterday with a diploma ceremony on its campus in Boston.
  • In addition, 20 students in the Doctoral Program earned PhD degrees in the fields of business administration, business economics, organizational behavior, and health policy management.
  • In November 2022, three students earned PhDs in business administration, health policy management, and organizational behavior.
  • During my lifetime, business has been an engine of prosperity in countries around the globe.

US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors

Retrieved on: 
Monday, January 2, 2023

RALEIGH, N.C., Jan. 2, 2023 /PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio', a blood test to help in the diagnosis of brain tumors. This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA. The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation.

Key Points: 
  • RALEIGH, N.C., Jan. 2, 2023 /PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio', a blood test to help in the diagnosis of brain tumors.
  • This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA.
  • The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation.
  • Diagnosis of brain tumors is risk-prone and brain biopsies are impossible to perform in almost 40% of advanced cases.

Arrow Electronics Announces ‘DANI’ (Data Analytics & Network Innovation) Project: Technology Solutions for People with Disabilities and Limited Mobility

Retrieved on: 
Thursday, May 19, 2022

Arrow Electronics (NYSE:ARW) today announced its new Data Analytics & Network Innovation Project, otherwise known as the DANI Project, helping to improve the lives of wheelchair users and those with limited mobility.

Key Points: 
  • Arrow Electronics (NYSE:ARW) today announced its new Data Analytics & Network Innovation Project, otherwise known as the DANI Project, helping to improve the lives of wheelchair users and those with limited mobility.
  • Uniquely, the data is specifically relevant to the needs of those in a wheelchair or with limited mobility.
  • DANI is an Edge computing project that brings computation and data storage closer to the source of data in this case, Dani.
  • Each technology is being developed by members of Arrows Graduate Programme; young employees who, like Dani, are digital natives in their 20s.

Artemis DNA Forays Into Multi-Billion Dollar Cancer Liquid Biopsy Market

Retrieved on: 
Monday, May 16, 2022

IRVINE, Calif. , May 16, 2022 /PRNewswire/ -- Artemis DNA, Inc. ("Artemis DNA" or the "company"), a leading USA-based diagnostic laboratory company, announced today that they will be offering revolutionary new cancer liquid biopsy tests through an exclusive partnership with Datar Cancer Genetics (Datar).  The agreement, a $250 million contract, grants Artemis DNA the exclusivity to be the only company that will commercialize and distribute the revolutionary cancer liquid biopsy tests, Trucheck Pragma and Cancertrack, in the USA and Vietnam.

Key Points: 
  • The $250 million contract gives Artemis DNA exclusivity to commercialize and distribute Trucheck Pragma and Cancertrack liquid biopsy tests in the USA and Vietnam.
  • IRVINE, Calif., May 16, 2022 /PRNewswire/ -- Artemis DNA, Inc.("Artemis DNA" or the "company"), a leading USA-based diagnostic laboratory company, announced today that they will be offering revolutionary new cancer liquid biopsy tests through an exclusive partnership with Datar Cancer Genetics (Datar).
  • The agreement, a $250 million contract, grants Artemis DNA the exclusivity to be the only company that will commercialize and distribute the revolutionary cancer liquid biopsytests,Trucheck Pragma and Cancertrack,in the USA and Vietnam.
  • Cancertrackis a cancer monitoring test for patients to evaluate response/resistance during treatment, as well as to monitor recurrence of cancer.

DATAR CANCER GENETICS ANNOUNCES FORAY INTO THE UNITED STATES WITH A $250M CONTRACT TO OFFER PIONEERING CANCER DETECTION LIQUID BIOPSIES

Retrieved on: 
Monday, May 9, 2022

Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.

Key Points: 
  • Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.
  • Their marketing strength and experience will enable a seamless roll-out of our innovative, game-changing, life-saving Liquid Biopsies," commented Mr. Rajan Datar, Chairman of Datar Cancer Genetics.
  • "Datar Cancer Genetics continues to innovate and push the boundaries on what people thought was impossible when it comes to cancer screening, diagnosis and management.
  • Datar Cancer Genetics is a global oncology research and applications company specializing in non-invasive technologies for improved detection, treatment, and management of cancer.

DATAR CANCER GENETICS ANNOUNCES FORAY INTO THE UNITED STATES WITH A $250M CONTRACT TO OFFER PIONEERING CANCER DETECTION LIQUID BIOPSIES

Retrieved on: 
Monday, May 9, 2022

Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.

Key Points: 
  • Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.
  • Their marketing strength and experience will enable a seamless roll-out of our innovative, game-changing, life-saving Liquid Biopsies," commented Mr. Rajan Datar, Chairman of Datar Cancer Genetics.
  • "Datar Cancer Genetics continues to innovate and push the boundaries on what people thought was impossible when it comes to cancer screening, diagnosis and management.
  • Datar Cancer Genetics is a global oncology research and applications company specializing in non-invasive technologies for improved detection, treatment, and management of cancer.

DATAR CANCER GENETICS ANNOUNCES FORAY INTO THE UNITED STATES WITH A $250M CONTRACT TO OFFER PIONEERING CANCER DETECTION LIQUID BIOPSIES

Retrieved on: 
Monday, May 9, 2022

Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.

Key Points: 
  • Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.
  • Their marketing strength and experience will enable a seamless roll-out of our innovative, game-changing, life-saving Liquid Biopsies," commented Mr. Rajan Datar, Chairman of Datar Cancer Genetics.
  • "Datar Cancer Genetics continues to innovate and push the boundaries on what people thought was impossible when it comes to cancer screening, diagnosis and management.
  • Datar Cancer Genetics is a global oncology research and applications company specializing in non-invasive technologies for improved detection, treatment, and management of cancer.

Artemis DNA, Genetic and Diagnostic Testing Company, Expands Services Internationally to Vietnam

Retrieved on: 
Monday, April 11, 2022

IRVINE, Calif., April 11, 2022 /PRNewswire/ -- Artemis DNA, Inc. ("Artemis DNA" or the "company"), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic testing that enables "personalized" medicine through early disease detection, proudly announced today that they will be opening their first international location at 253A Hoàng Sa, Phường Đa Kao, Quận 1 in Ho Chi Minh City, Vietnam.  Starting April 2022, Artemis DNA will begin offering its genetic testing technology and portfolio, as well as a new, revolutionary cancer screening called Trucheck™ Pragma through a partnership with Datar Cancer Genetics (Datar), a leading cancer research corporation specializing in non-invasive techniques for better diagnosis, treatment decisions, and management of cancer based in India and the United Kingdom.  The test, which was developed by Datar, uses blood samples and is intended for early detection of Prostate (men), Breast and Ovary (women), in addition to Lung, Stomach, and Colon/Pancreas cancers.

Key Points: 
  • Artemis DNA will begin offering groundbreaking cutting-edge genetic testing and early cancer detection technology to the people of Vietnam.
  • "TrucheckPragma is truly a remarkable advancement in cancer screening," commentedMs.Emylee Thai, Founder and Chairwoman of Artemis DNA.
  • The team at Artemis DNA is very excited to bring this cutting-edge technology for the people of Vietnam."
  • Artemis DNA also provides pre- and post-testing genetic education and counseling services, as well as conducting research and development to discover and develop additional novel diagnostic services.